Statin initiation in dialysis patients: The hardship of non-prescription

“In adults with dialysis-dependent chronic kidney disease (CKD [5D]), we suggest that statins or statin/ezetimibe combination not be initiated.” This recommendation statement was issued in 2013 by the Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group [1]. The quality of the supp orting evidence was graded A (high), but the strength of the recommendation (level 2) implied that “different choices will be appropriate for different patients”. Against this background, which encompasses considerable precaution, it is not unreasonable to reconsider statin initiation in dialysi s patients.
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research

Related Links:

In this study, they found these drugs can kill senescent cells from cultures of human fat tissue. The tissue was donated by individuals with obesity who were known to have metabolic troubles. Without treatment, the human fat tissues induced metabolic problems in immune-deficient mice. After treatment with dasatinib and quercetin, the harmful effects of the fat tissue were almost eliminated. Targeting p21Cip1 highly expressing cells in adipose tissue alleviates insulin resistance in obesity Insulin resistance is a pathological state often associated with obesity, representing a major risk factor for type 2...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In this commentary, scientists note the paucity of funding for chronic kidney disease research, given the widespread suffering and death caused by this presently incurable condition. This and many other areas of medicine are seen as solved problems by the powers that be simply because there is some form of treatment, even palliative treatment, in widespread use. That the treatment does little and many people die doesn't appear to motivate those who could fund progress. There is no sense of urgency and little sense of need. We might make the same comments in the case of atherosclerosis, a condition many consider to be adequ...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
In conclusion, female sex, smoking, and CKD stage 5D were the major risk factors for elevated BCL; additionally, statins were negatively associated with BCL in CKD.
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
In conclusion, premature thymic involution and chronic inflammation greatly contribute to increased morbidity and mortality in CKD patients. Mechanisms are likely to be multiple and interlinked. Even when the quest to fountain of youth is a pipe dream, there are many scientific opportunities to prevent or to, at least in part, reverse CKD-related immune senescence. Further studies should precisely define most important pathways driving premature immune ageing in CKD patients and best therapeutic options to control them. Extending Life Without Extending Health: Vast Effort Directed to the Wrong Goals https://www...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Cardiovascular risk increases as glomerular filtration rate (GFR) declines in progressive renal disease and is maximal in patients with end-stage renal disease requiring maintenance dialysis. Atherosclerotic vascular disease, for which hyperlipidemia is the main risk factor and lipid-lowering therapy is the key intervention, is common. However, the pattern of dyslipidemia changes with low GFR and the association with vascular events becomes less clear. While the pathophysiology and management of patients with early chronic kidney disease (CKD) is similar to the general population, advanced and end-stage CKD is characterize...
Source: Cardiology Clinics - Category: Cardiology Authors: Source Type: research
This article focuses on epidemiology of CKD, how dyslipidemias confer a higher risk for CVD, the approach to management and treatment of dyslipidemias, and recent guidelines.
Source: Cardiology Clinics - Category: Cardiology Authors: Source Type: research
CONCLUSIONS: Our finding indicates that statin could improve all-cause and cardiovascular mortality in patients with non-dialysis CKD.PMID:33829456 | DOI:10.26355/eurrev_202103_25433
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSIONS: For patients with advanced CKD, continuing fenofibrate may provide a protective effect on CV outcomes equal to that of statins, and it may further delay the need for permanent dialysis. The combination of fenofibrate and high intensity statins may have additional benefits.PMID:33677489 | DOI:10.1210/clinem/dgab137
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Source Type: research
Background and Aims: In dialysis patients statins are less effective than in other high risk patients due to a shift from cholesterol synthesis towards cholesterol absorption. The CARE FOR HOMe study investigates whether the ratio of campesterol-to-lathosterol predicts cardiovascular outcomes in CKD patients not on dialysis.
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research
More News: Cardiology | Cholesterol | Chronic Kidney Disease | Dialysis | Statin Therapy | Urology & Nephrology | Vytorin | Zetia